

3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Excelerate Health Ventures III | April 2026 | Indefinite | $22M | 50 |
| Excelerate Health Ventures II | 2021 | Indefinite | $35M | 105 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Andrew Schwab | Slowing | Biotech & pharma, Digital health, E-commerce & marketplaces | 19 | 1 |
| Bobby Bahram | Quiet | Digital health, Data & analytics, Education | 7 | 0 |
| Maulik Mehta | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Excelerate Health Ventures’s own portfolio companies, based on 17 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Excelerate Health Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Hatteras Venture Partners | 3 | BEKHealth, Bivarus, Huma.AI |
| Altitude Ventures | 2 | Doctivity, Itiliti Health |
| Arboretum Ventures | 2 | Pear Therapeutics, RareCyte |
| Resolute Venture Partners | 2 | Doctivity, Itiliti Health |
| BIP Ventures | 1 | Korio |
| OCA Ventures | 1 | Atalan Tech |
| Orbimed Genesis | 1 | Cleave Biosciences |
| Polaris Partners | 1 | Camp4 Therapeutics |
| ShangBay Capital | 1 | Huma.AI |
| Transformation Capital | 1 | Assay Depot |
| U.S Venture Partners | 1 | Cleave Biosciences |
| Versant Venture Capital | 1 | BIRD ROCK BIO |
| Westlake Biopartners | 1 | Precision Nanosystems |
A shared board seat: a company where filings name a Excelerate Health Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.